Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 82,520,576
  • Shares Outstanding, K 105,099
  • Annual Sales, $ 14,202 M
  • Annual Income, $ 4,413 M
  • EBIT $ 3,688 M
  • EBITDA $ 4,171 M
  • 60-Month Beta 0.37
  • Price/Sales 5.77
  • Price/Cash Flow 17.05
  • Price/Book 2.65

Options Overview Details

View History
  • Implied Volatility 30.72% (+0.01%)
  • Historical Volatility 33.37%
  • IV Percentile 7%
  • IV Rank 13.33%
  • IV High 60.01% on 04/08/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 1) 4.25 (0.54%)
  • Put/Call Vol Ratio 1.11
  • Today's Volume 2,980
  • Volume Avg (30-Day) 2,049
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 50,910
  • Open Int (30-Day) 55,907
  • Expected Range 779.46 to 787.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 8.06
  • Number of Estimates 6
  • High Estimate 10.82
  • Low Estimate 6.92
  • Prior Year 9.90
  • Growth Rate Est. (year over year) -18.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
691.86 +13.28%
on 12/09/25
792.77 -1.14%
on 12/24/25
+22.26 (+2.92%)
since 11/24/25
3-Month
541.00 +44.86%
on 10/13/25
792.77 -1.14%
on 12/24/25
+206.73 (+35.83%)
since 09/24/25
52-Week
476.49 +64.48%
on 06/05/25
792.77 -1.14%
on 12/24/25
+69.24 (+9.69%)
since 12/24/24

Most Recent Stories

More News
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent...

SAN.FP : 81.610 (-0.74%)
REGN : 783.71 (-0.19%)
SNY : 48.36 (+0.08%)
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:  REGN ) will webcast its presentation at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January...

REGN : 783.71 (-0.19%)
Pfizer Adds to Its Big Bet on Weight Loss Drugs

A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.

NVO : 52.56 (+1.84%)
JNJ : 207.78 (+0.97%)
LLY : 1,076.98 (+0.50%)
REGN : 783.71 (-0.19%)
PFE : 25.03 (+0.60%)
2 Large-Cap Stocks on Our Buy List and 1 We Find Risky

2 Large-Cap Stocks on Our Buy List and 1 We Find Risky

NOW : 152.59 (-1.15%)
PGR : 227.66 (-0.10%)
REGN : 783.71 (-0.19%)
3 Low-Volatility Stocks We’re Skeptical Of

3 Low-Volatility Stocks We’re Skeptical Of

CMCSA : 29.78 (+1.36%)
REGN : 783.71 (-0.19%)
KFY : 66.65 (+0.20%)
Lynozyficâ„¢ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these...

REGN : 783.71 (-0.19%)
3 Cash-Producing Stocks We Find Risky

3 Cash-Producing Stocks We Find Risky

HLMN : 8.99 (+0.22%)
OGN : 7.09 (unch)
REGN : 783.71 (-0.19%)
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

NVDA : 188.61 (-0.32%)
XLV : 155.80 (+0.52%)
JNJ : 207.78 (+0.97%)
LLY : 1,076.98 (+0.50%)
IBB : 173.25 (+0.67%)
GILD : 125.67 (+0.38%)
REGN : 783.71 (-0.19%)
AMGN : 333.96 (+0.75%)
UNH : 327.58 (+0.86%)
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million,...

REGN : 783.71 (-0.19%)
Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500?

Regeneron Pharmaceuticals has underperformed the S&P 500 over the past year, but analysts are cautiously optimistic about the stock’s prospects.

$SPX : 6,932.05 (+0.32%)
INCY : 100.44 (-0.47%)
REGN : 783.71 (-0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 798.94
2nd Resistance Point 795.86
1st Resistance Point 789.78
Last Price 783.71
1st Support Level 780.62
2nd Support Level 777.54
3rd Support Level 771.46

See More

52-Week High 792.77
Last Price 783.71
Fibonacci 61.8% 671.95
Fibonacci 50% 634.63
Fibonacci 38.2% 597.31
52-Week Low 476.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar